Relationship between cytomegalovirus (CMV) reactivation, CMV-driven immunity, overall immune recovery and graft-versus-leukaemia effect in children

British Journal of Haematology

Volumn 166, Issue 2, 2014, Pages 229-239

  Jeljeli, Mohamed ^a   Guérin El Khourouj, Valérie ^a   Porcher, Raphael ^b   Fahd, Mony ^a   Leveillé, Sandrine ^a   Yakouben, Karima ^a   Ouachée Chardin, Marie ^a   Legoff, Jerome ^b   Cordeiro, Debora Jorge ^a   Pédron, Beatrice ^a   Baruchel, Andre ^a   Dalle, Jean Hugues ^a   Sterkers, Ghislaine ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Children; Cytomegalovirus; Haematopoietic stem cell transplantation; Immune recovery; Relapse risk

Indexed keywords

ACICLOVIR; BUSULFAN; CD135 ANTIGEN; CD45RA ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FOSCARNET; GAMMA INTERFERON; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; L SELECTIN; METHOTREXATE; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CELL EXPANSION; CELL PROLIFERATION; CHILD; CHILDHOOD LEUKEMIA; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; DONOR; DRUG DOSE REDUCTION; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; IMMUNE RESPONSE; INFANT; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LYMPHOCYTE SUBPOPULATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NONMYELOABLATIVE CONDITIONING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SEROLOGY; SIBLING; T LYMPHOCYTE; VIRUS LOAD; VIRUS REACTIVATION; WHOLE BODY RADIATION;

CHILDREN; CYTOMEGALOVIRUS; HAEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNE RECOVERY; RELAPSE RISK;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY, CELLULAR; INFANT; INFANT, NEWBORN; LEUKEMIA; MALE; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME; VIREMIA; VIRUS ACTIVATION;

EID: 84903699744     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12875     Document Type: Article

References (35)

1. Abate, D., Cesaro, S., Cofano, S., Fiscon, M., Saldan, A., Varotto, S., Mengoli, C., Pillon, M., Calore, E., Biasolo, M.A., Cusinato, R., Barzon, L., Messina, C., Carli, M. & Palu, G. (2012) Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients. Transplantation, 93, 536-542.
2. Armand, P., Gibson, C.J., Cutler, C., Ho, V.T., Koreth, J., Alyea, E.P., Ritz, J., Sorror, M.L., Lee, S.J., Deeg, H.J., Storer, B.E., Appelbaum, F.R., Antin, J.H., Soiffer, R.J. & Kim, H.T. (2012) A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood, 120, 905-913.
3. Behrendt, C.E., Rosenthal, J., Bolotin, E., Nakamura, R., Zaia, J. & Forman, S.J. (2009) Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy. Biology of Blood and Marrow Transplantation, 15, 54-60.
4. de Berranger, E., Cousien, A., Petit, A., Peffault de Latour, R., Galambrun, C., Bertrand, Y., Salmon, A., Rialland, F., Rohrlich, P.S., Vannier, J.P., Lutz, P., Yakouben, K., Duhamel, A., Bruno, B., Michel, G. & Dalle, J.H. (2014) Impact on long-term OS of conditioning regimen in allogeneic BMT for children with AML in first CR: TBI+CY versus BU+CY: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Bone Marrow Transplantation, 49, 382-388.
5. Bordon, V., Bravo, S., Van Renterghem, L., de Moerloose, B., Benoit, Y., Laureys, G. & Dhooge, C. (2008) Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease. Transplant Infectious Disease, 10, 19-23.
6. Development Core Team, R. (2011) A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria.
7. Eapen, M. & Wagner, J.E. (2010) Transplant outcomes in acute leukemia. I. Seminars in Hematology, 47, 46-50.
8. Elmaagacli, A.H., Steckel, N.K., Koldehoff, M., Hegerfeldt, Y., Trenschel, R., Ditschkowski, M., Christoph, S., Gromke, T., Kordelas, L., Ottinger, H.D., Ross, R.S., Horn, P.A., Schnittger, S. & Beelen, D.W. (2011) Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood, 118, 1402-1412.
9. Fletcher, J.M., Vukmanovic-Stejic, M., Dunne, P.J., Birch, K.E., Cook, J.E., Jackson, S.E., Salmon, M., Rustin, M.H. & Akbar, A.N. (2005) Cytomegalovirus-specific CD4+ T cells in healthy carriers are continuously driven to replicative exhaustion. Journal of Immunology, 175, 8218-8225.
10. Gooley, T.A., Chien, J.W., Pergam, S.A., Hingorani, S., Sorror, M.L., Boeckh, M., Martin, P.J., Sandmaier, B.M., Marr, K.A., Appelbaum, F.R., Storb, R. & McDonald, G.B. (2010) Reduced mortality after allogeneic hematopoietic-cell transplantation. The New Journal England of Medicine, 363, 2091-2101.
11. Grambsch, P.M. & Therneau, T.M. (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika, 81, 515-526.
12. Green, M.L., Leisenring, W.M., Xie, H., Walter, R.B., Mielcarek, M., Sandmaier, B.M., Riddell, S.R. & Boeckh, M. (2013) CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood, 122, 1316-1324.
13. Guerin, V., Dalle, J.H., Pedron, B., Ouachee-Chardin, M., Yakouben, K., Baruchel, A. & Sterkers, G. (2010) Cellular immune parameters associated with spontaneous control of CMV in children who underwent transplantation. Bone Marrow Transplantation, 45, 442-449.
14. Hochberg, J., Khaled, S., Forman, S.J. & Cairo, M.S. (2013) Criteria for and outcomes of allogeneic haematopoietic stem cell transplant in children, adolescents and young adults with acute lymphoblastic leukaemia in first complete remission. British Journal of Haematology, 161, 27-42.
15. Horowitz, M.M., Gale, R.P., Sondel, P.M., Goldman, J.M., Kersey, J., Kolb, H.J., Rimm, A.A., Ringden, O., Rozman, C. & Speck, B. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 75, 555-562.
16. Ito, S., Pophali, P., Co, W., Koklanaris, E.K., Superata, J., Fahle, G.A., Childs, R., Battiwalla, M. & Barrett, A.J. (2013) CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML. Bone Marrow Transplantation, 48, 1313-1316.
17. Kalbfleisch, J.D. & Prentice, R.L. (1980) The Statistical Analysis of Failure Time Data. John Wiley & Sons, New York, NY.
18. Kreutzman, A., Ladell, K., Koechel, C., Gostick, E., Ekblom, M., Stenke, L., Melo, T., Einsele, H., Porkka, K., Price, D.A., Mustjoki, S. & Seggewiss, R. (2011) Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia, 25, 1587-1597.
19. Lilleri, D., Gerna, G., Fornara, C., Chiesa, A., Comolli, G., Zecca, M. & Locatelli, F. (2009) Human cytomegalovirus-specific T cell reconstitution in young patients receiving T cell-depleted, allogeneic hematopoietic stem cell transplantation. The Journal of Infectious Diseases, 199, 829-836.
20. Locatelli, F., Schrappe, M., Bernardo, M.E. & Rutella, S. (2012) How I treat relapsed childhood acute lymphoblastic leukemia. Blood, 120, 2807-2816.
21. Lonnqvist, B., Ringden, O., Ljungman, P., Wahren, B. & Gahrton, G. (1986) Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection. British Journal of Haematology, 63, 671-679.
22. de Masson, A., Bouaziz, J.D., Peffault de Latour, R., Wittnebel, S., Ribaud, P., Rubio, M.T., Micol, J.B., Suarez, F., Nguyen, S., Dalle, J.H., Yakouben, K., Robin, M., Xhaard, A., Ades, L., Bourhis, J.H., Rybojad, M., Bagot, M. & Socie, G. (2012) Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD. Blood, 120, 5089-5090.
23. Matthes-Martin, S., Feuchtinger, T., Shaw, P.J., Engelhard, D., Hirsch, H.H., Cordonnier, C. & Ljungman, P. (2012) European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). Transplant Infectious Disease, 14, 555-563.
24. Merindol, N., Salem Fourati, I., Brito, R.M., Grenier, A.J., Charrier, E., Cordeiro, P., Caty, M., Mezziani, S., Malette, B., Duval, M., Alfieri, C., Ovetchkine, P., Le Deist, F. & Soudeyns, H. (2012) Reconstitution of protective immune responses against cytomegalovirus and varicella zoster virus does not require disease development in pediatric recipients of umbilical cord blood transplantation. Journal of Immunology, 189, 5016-5028.
25. Nakamura, R., Battiwalla, M., Solomon, S., Follmann, D., Chakrabarti, S., Cortez, K., Hensel, N., Childs, R. & Barrett, A.J. (2004) Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure. Biology of Blood and Marrow Transplantation, 10, 49-57.
26. Parkman, R., Cohen, G., Carter, S.L., Weinberg, K.I., Masinsin, B., Guinan, E., Kurtzberg, J., Wagner, J.E. & Kernan, N.A. (2006) Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. Biology of Blood and Marrow Transplantation, 12, 919-927.
27. Pedron, B., Guerin, V., Cordeiro, D.J., Masmoudi, S., Dalle, J.H. & Sterkers, G. (2011) Development of cytomegalovirus and adenovirus-specific memory CD4 T-cell functions from birth to adulthood. Pediatric Research, 69, 106-111.
28. Prentice, R.L., Kalbfleisch, J.D., Peterson, A.V. Jr, Flournoy, N., Farewell, V.T. & Breslow, N.E. (1978) The analysis of failure times in the presence of competing risks. Biometrics, 34, 541-554.
29. Rager, A. & Porter, D.L. (2011) Cellular therapy following allogeneic stem-cell transplantation. Therapeutic Advances in Hematology, 2, 409-428.
30. Ringden, O. & Horowitz, M.M. (1989) Graft-versus-leukemia reactions in humans. The Advisory Committee of the International Bone Marrow Transplant Registry. Transplantation Proceedings, 21, 2989-2992.
31. Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W.D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M.F. & Velardi, A. (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science, 295, 2097-2100.
32. Wang, Y., Liu, D.H., Xu, L.P., Liu, K.Y., Chen, H., Chen, Y.H., Han, W., Shi, H.X. & Huang, X.J. (2011) Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison. Biology of Blood and Marrow Transplantation, 17, 821-830.
33. Williams, K.M. & Gress, R.E. (2008) Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation. Best Practice & Research Clinical Haematology, 21, 579-596.
34. Yakoub-Agha, I., Saule, P., Magro, L., Cracco, P., Duhamel, A., Coiteux, V., Bruno, B., Dufosse, F., Jouet, J.P., Dessaint, J.P. & Labalette, M. (2009) Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+ T cells on relapse. Biology of Blood and Marrow Transplantation, 15, 496-504.
35. Zhang, M.J., Davies, S.M., Camitta, B.M., Logan, B., Tiedemann, K., Eapen, M. & Thiel, E.L. (2012) Comparison of outcomes after HLA-matched sibling and unrelated donor transplantation for children with high-risk acute lymphoblastic leukemia. Biology of Blood and Marrow Transplantation, 18, 1204-1210.